Department of Medicine, Memorial Sloan Kettering Cancer Center, Cornell University, New York; Weill Medical College, Cornell University, New York and Trinity College Dublin, Ireland
Ghassan Abou-Alfa is an Attending Physician at Memorial Sloan Kettering Cancer Center (MSK) and Professor of Medicine at Weill Medical School at Cornell University. He specializes in in the treatment of GI malignancies and in particular, hepatocellular carcinoma (HCC), intrahepatic and extrahepatic cholangiocarcinoma (IHC), gallbladder cancer (GB), and fibrolamellar carcinoma (FLC). Professor Abou-Alfa is a member of the Steering Committee of the International Affairs Committee of the American Society of Clinical Oncology (ASCO). He is the immediate past-President for the International Society of Gastrointestinal Oncology (ISGIO), immediate past Chair of the NCI Hepatobiliary Taske Force, and current Vice-Chair of the NCI AIDS Malignancu Consprtium Solid Tuors Working Groiup. Professor Abou-Alfa majored in biology, earned his medical degree, and now serves as a trustee on the Board of Trustees of the American University in Beirut (AUB). Professor Abou-Alfa completed his postdoctoral training in internal medicine, medical oncology, and hematology at Yale University, received his MBA from Columbia University, and is completing his JD at Fordham University.
Professor Abou-Alfa envisions the universal quest for health, embodied by physicians upholding humanistic ideals, supersedes geopolitics among the world’s people. Recognizing germline alterations as an endless opportunity to explore cancer related environmental and other genetic risk factors gloablly. Professor Abou-Alfa global effort is studying humanity cancer germline convergence and divergence cancer predispositions worldwide. Professor Abou-Alfa strongly advocates for greater awareness of cancer’s global impact; and continues to lead several international educational and research efforts with different institutions worldwide. Professor Abou-Alfa spearheaded many projects worldwide.
Session 17: Evaluating Current and Emerging Targeted Therapies in Hepatocellular Carcinoma
Saturday, April 1, 2023
10:45 AM – 11:30 AM ET
Session 19: Determination of Treatment Patterns in HCC
Friday, August 4, 2023
1:30 PM – 2:15 PM ET
Session 6: Current and Emerging Therapies in Hepatocellular Carcinoma
Thursday, September 28, 2023
2:20 PM – 2:55 PM ET
Thursday, September 28, 2023
2:55 PM – 3:05 PM ET